Baxter International Yönetim

Yönetim kriter kontrolleri 3/4

Baxter International CEO'su Joe Almeida, Jan2016 tarihinde atandı, in görev süresi 8.92 yıldır. in toplam yıllık tazminatı $ 13.79M olup, şirket hissesi ve opsiyonları dahil olmak üzere 9.4% maaş ve 90.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.11% ine doğrudan sahiptir ve bu hisseler € 15.75M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.2 yıl ve 4.8 yıldır.

Anahtar bilgiler

Joe Almeida

İcra Kurulu Başkanı

US$13.8m

Toplam tazminat

CEO maaş yüzdesi	9.4%
CEO görev süresi	8.9yrs
CEO sahipliği	0.1%
Yönetim ortalama görev süresi	2.2yrs
Yönetim Kurulu ortalama görev süresi	4.8yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Joe Almeida'un ücretlendirmesi Baxter International'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	US$121m
Jun 30 2024	n/a	n/a	US$98m
Mar 31 2024	n/a	n/a	-US$38m
Dec 31 2023	US$14m	US$1m	-US$76m
Sep 30 2023	n/a	n/a	US$96m
Jun 30 2023	n/a	n/a	-US$3b
Mar 31 2023	n/a	n/a	-US$3b
Dec 31 2022	US$14m	US$1m	-US$3b
Sep 30 2022	n/a	n/a	-US$3b
Jun 30 2022	n/a	n/a	US$876m
Mar 31 2022	n/a	n/a	US$992m
Dec 31 2021	US$16m	US$1m	US$1b
Sep 30 2021	n/a	n/a	US$1b
Jun 30 2021	n/a	n/a	US$1b
Mar 31 2021	n/a	n/a	US$1b
Dec 31 2020	US$16m	US$1m	US$1b
Sep 30 2020	n/a	n/a	US$911m
Jun 30 2020	n/a	n/a	US$924m
Mar 31 2020	n/a	n/a	US$991m
Dec 31 2019	US$14m	US$1m	US$1b
Sep 30 2019	n/a	n/a	US$1b
Jun 30 2019	n/a	n/a	US$1b
Mar 31 2019	n/a	n/a	US$2b
Dec 31 2018	US$16m	US$1m	US$2b
Sep 30 2018	n/a	n/a	US$1b
Jun 30 2018	n/a	n/a	US$795m
Mar 31 2018	n/a	n/a	US$840m
Dec 31 2017	US$15m	US$1m	US$609m

Tazminat ve Piyasa: Joe 'nin toplam tazminatı ($USD 13.79M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 4.86M ).

Tazminat ve Kazançlar: Joe 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Joe Almeida (62 yo)

8.9yrs

Görev süresi

US$13,786,671

Tazminat

Mr. Jose E. Almeida, also known as Joe, has been the Chairman of the Board and Chief Executive Officer of Baxter International Inc. since January 1, 2016 and serves as its President since January 01, 2016....

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jose Almeida	Chairman of the Board	8.9yrs	US$13.79m	0.11% € 15.7m
Joel Grade	Executive VP	1.2yrs	US$5.37m	0.0028% € 391.7k
Heather Knight	Executive VP & Group President of Medical Products and Therapies	1.8yrs	US$4.86m	0.031% € 4.4m
Alok Sonig	Executive VP & Group President of Pharmaceuticals	2.4yrs	US$3.87m	0.0024% € 333.8k
Christopher Toth	Executive VP & Group President of Kidney Care	1.5yrs	US$9.64m	0.0046% € 644.9k
Tobi Karchmer	Senior VP and Chief Medical & Scientific Officer	1.9yrs	Veri yok	Veri yok
Charles Patel	Senior VP & Chief Information Officer	less than a year	Veri yok	Veri yok
Clare Trachtman	Vice President of Investor Relations	no data	Veri yok	Veri yok
David Rosenbloom	Executive VP & General Counsel	2.7yrs	US$5.66m	0.0018% € 256.0k
Stacey Eisen	Senior Vice President	no data	Veri yok	Veri yok
Jeanne Mason	Executive VP & Chief Human Resources Officer	7.6yrs	US$4.14m	0.037% € 5.2m
James Borzi	Executive VP & Chief Supply Chain Officer	4.9yrs	Veri yok	0.0036% € 507.7k

2.2yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim: BTL 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jose Almeida	Chairman of the Board	8.9yrs	US$13.79m	0.11% € 15.7m
Stephen Rusckowski	Independent Director	1.3yrs	US$197.82k	0.0018% € 251.7k
Robert Parkinson	Chairman Emeritus	8.9yrs	US$17.88m	Veri yok
Peter Wilver	Independent Director	2.6yrs	US$349.64k	0.0026% € 367.7k
Stephen Newman Oesterle	Independent Director	7.8yrs	US$373.98k	0.0055% € 772.2k
Patricia Morrison	Independent Director	5.8yrs	US$364.98k	0.0042% € 591.1k
Nancy Schlichting	Independent Director	3yrs	US$363.00k	0.0028% € 396.0k
Catherine Smith	Independent Director	7.9yrs	US$367.31k	0.0044% € 625.1k
David Shafer	Lead Independent Director	2.6yrs	US$382.31k	0.0026% € 367.7k
David Wilkes	Independent Director	3.8yrs	US$357.00k	0.0032% € 451.1k
William Ampofo	Independent Director	1.5yrs	US$226.35k	0.0019% € 272.9k
Amy Wendell	Independent Director	5.8yrs	US$352.98k	Veri yok

4.8yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: BTL 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.8 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/20 13:23
Gün Sonu Hisse Fiyatı	2024/12/20 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Baxter International Inc. 46 Bu analistlerden 13, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Jasper Hellweg	Argus Research Company
Benjamin Yeoh	Atlantic Equities LLP
Daniel Owczarski	Avondale Partners

Baxter International Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Baxter International Inc. Announces Resignation of Peter M. Wilver as Board of Directors, and the Audit Committee and Compensation and Human Capital Committee, Effective December 31, 2024

-Baxter International Inc. Appoints Jeffrey A. Craig to Its Board

Baxter International Inc., Annual General Meeting, May 07, 2024

Baxter International Inc. Announces Management Appointments

Baxter International Inc. Announces Board Changes

High number of new directors

Recent updates

Baxter International Inc. Announces Continued Growth of Pharmaceuticals Portfolio with Five Injectable Product Launches in the U.S

Baxter International Inc. Announces Resignation of Peter M. Wilver as Board of Directors, and the Audit Committee and Compensation and Human Capital Committee, Effective December 31, 2024

Baxter International Inc. Declares Quarterly Dividend, Payable on January 2, 2025

Baxter International Inc. Declares Quarterly Dividend, Payable on January 2, 2025

Baxter International Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2024

Baxter International Inc. Provides Update on North Cove, N.C., Facility

-Baxter International Inc. Appoints Jeffrey A. Craig to Its Board

Upcoming dividend of US$0.29 per share

The Carlyle Group Inc. (NasdaqGS:CG) and Atmas Health entered into an Equity Purchase Agreement to acquire Vantive Health LLC from Baxter International Inc. (NYSE:BAX) for $3.8 billion.

Second quarter 2024 earnings released: US$0.62 loss per share (vs US$0.39 loss in 2Q 2023)

Baxter International Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2024

Baxter International Inc. Announces Launch of the Helion Integrated Surgical System in Thailand

First quarter dividend of US$0.29 announced

Baxter International Inc. Declares Quarterly Dividend, Payable on October 1, 2024

Carlyle Group Reportedly in Advanced Talks to Buy Baxter's Vantive Business

Baxter International Inc. Announces New Data Showing Expanded Hemodialysis, Known as HDX Therapy

Upcoming dividend of US$0.29 per share

Baxter International Inc. Secures FDA Approval of Clinolipid (Lipid Injectable Emulsion) Neonatal and Pediatric Indication

First quarter dividend of US$0.29 announced

Baxter International Inc. Declares Quarterly Dividend, Payable on July 1, 2024

Baxter International Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2024

First quarter 2024 earnings released: EPS: US$0.073 (vs US$0.002 loss in 1Q 2023)

Baxter International Inc. Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S

Baxter International Inc. Announces U.S. FDA Clearance of Novum IQ Large Volume Infusion Pump and Dose IQ Safety Software, Advancing Connected and Intelligent Infusion Therapy

Baxter International Inc., Annual General Meeting, May 07, 2024

Upcoming dividend of US$0.29 per share

Fourth quarter dividend of US$0.29 announced

Full year 2023 earnings released: US$0.15 loss per share (vs US$4.83 loss in FY 2022)

Baxter International Inc. Provides Sales Guidance for the First Quarter and Full Year 2024

Now 21% overvalued after recent price rise

Baxter International Inc. Announces the Completion of the First Phase of Its Intravenous (IV) Bag Recycling Program Pilot

Upcoming dividend of US$0.29 per share at 3.2% yield

Baxter International Inc. Declares Quarterly Dividend, Payable on January 2, 2024

Baxter International Inc. Highlights New Data At Kidney Week Indicating Sharesource Is Associated with A 77% Lower Risk of Home Dialysis Technique Failure

Baxter International Inc. Provides Earnings Guidance for the Fourth Quarter and Year 2023

Third quarter 2023 earnings released: EPS: US$0.095 (vs US$5.83 loss in 3Q 2022)

Baxter International Inc. Digital Image Capture Capability for PanOptic Plus Ophthalmoscope

Baxter International Inc. Announces Management Appointments

Levi & Korsinsky Notifies Baxter International Inc. Investors of A Class Action Lawsuit and Upcoming Deadline

Upcoming dividend of US$0.29 per share at 2.8% yield

Baxter International Inc. Announces Board Changes

The Klein Law Firm Announces That A Class Action Complaint Has Been Filed on Behalf of Shareholders of Baxter International Inc. Alleging That the Company Violated Federal Securities Laws

Second quarter 2023 earnings released: US$0.39 loss per share (vs US$0.36 profit in 2Q 2022)

Baxter International Inc. Launches PERCLOT Absorbable Hemostatic Powder

Baxter International Inc. Declares Quarterly Cash Dividend, Payable on October 2, 2023

Rosen Law Firm Announces the Filing of Class Action Lawsuit on Behalf of Purchasers of Securities of Baxter International Inc

High number of new directors

Baxter International Inc. Appoints William Ampofo to Its Board of Directors

Baxter International Inc.(NYSE:BAX) dropped from Russell 1000 Growth Index

Upcoming dividend of US$0.29 per share at 2.8% yield

Baxter International Inc. Announces James K. Saccaro Notifies to Resign as Executive Vice President, Effective as of May 31, 2023

Advent International Corporation and Warburg Pincus LLC signed a definitive agreement to acquire Baxter Pharmaceutical Solutions LLC from Baxter International Inc. (NYSE:BAX) for $4.3 billion.

Baxter International Inc. Selects Chris Toth to Be Chief Executive Officer of the Company’s Planned Spinoff of Its Renal Care and Acute Therapies Businesses

First quarter 2023 earnings released: EPS: US$0.087 (vs US$0.14 in 1Q 2022)

Baxter International Inc. Announces Management Changes

Baxter International Inc. Declares Quarterly Dividend, Payable on April 3, 2023

Full year 2022 earnings released: US$4.83 loss per share (vs US$2.56 profit in FY 2021)

Baxter International Inc. Reports Goodwill Impairment for the Fourth Quarter Ended December 31, 2022

Baxter International Inc. Announces Resignation of Giuseppe Accogli as Executive Vice President and Chief Operating Officer

Baxter Introduces ExactaMix Pro Automated Compounder

Upcoming dividend of US$0.29 per share

Baxter International Inc. Declares Quarterly Cash Dividend, Payable on January 3, 2023

Baxter International Inc. Highlights New Home Dialysis and HDX Therapy Data in 14 Clinical Presentations At Kidney Week 2022

Third quarter 2022 earnings released: US$5.83 loss per share (vs US$0.90 profit in 3Q 2021)

Baxter International Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022

Baxter International Inc. to Report Q3, 2022 Results on Oct 27, 2022

Baxter International Inc. Announces U.S. FDA Clearance of Novum IQ Syringe Infusion Pump with Dose IQ Safety Software

Upcoming dividend of US$0.29 per share

Second quarter 2022 earnings released: EPS: US$0.25 (vs US$0.59 in 2Q 2021)